

Report from the Annual General Meeting of Dicot Pharma

Uppsala, Sweden, May 6, 2026. Dicot Pharma AB held its Annual General Meeting today in Uppsala where the following decisions were made.

Annual report and results

The meeting adopted the income statements and balance sheets for 2025 according to the accounting documents presented and decided in accordance with the Board's proposal that the profit for the year be carried forward. No dividend will be paid.

Discharge from liability

The Meeting discharged the members of the Board of Directors and the Managing Director from liability for the management of the company's affairs during the financial year 2025.

Election of the Board of Directors and auditor

It was resolved to re-elect Eva Sjökvist Saers, Fredrik Buch, Mikael von Euler, Per-Göran Gillberg and Jan-Eric Österlund as ordinary Directors. Eva Sjökvist Saers was re-elected as Chairman of the Board. The Meeting resolved to re-elect Öhrlings PricewaterhouseCoopers AB as auditor with Lars Kylberg as auditor in charge.

Board and auditor fees

It was resolved that Board fees shall be paid in the amount of SEK 150,000 for ordinary Directors and SEK 300,000 for the Chairman, an increase of SEK 25,000 and SEK 50,000 respectively. It was resolved that the auditor's fee shall be paid on current account.

Resolution on the Nomination Committee

The AGM resolved that Dicot Pharma, prior to the 2027 AGM, shall have a nomination committee that shall submit proposals for, among other things, Directors, Board fees, and auditor. The members of the Nomination Committee are appointed by the Chairman of the Board contacting the three largest shareholders in the company as of September 30, 2026, and asking them to appoint one representative each to constitute the Nomination Committee together with the Chairman of the Board.

Employee stock option program 2026/2031

The AGM resolved to introduce an incentive program for employees and the CEO through a directed issue of warrants to Dicot Pharma (with approval for onward transfer to the participants in the program). The program entails an issue of not more than 6,500,000 warrants, of which 5,000,000 warrants are allocated to the participants and 1,500,000 warrants are issued to cover social security contributions.

Resolution on a general authorization

The AGM resolved to authorize the board of directors for the time until the next annual general meeting, whether on one or several occasions, to within the limits of the articles of association resolve on issues of shares, warrants and/or convertible instruments with or without deviation from the shareholders' pre-emption rights.

The above resolutions were passed with the required majority. For more detailed information on the content of the resolutions, please refer to the full notice of the Annual General Meeting available at www.dicotpharma.com .

For further information, please contact:

Elin Trampe, CEO

Phone: +46 72 502 10 10

E-mail: elin.trampe@dicotpharma.com

About Dicot Pharma AB

Dicot Pharma is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at USD 8 billion. Dicot Pharma's business model involves evaluating industrial and financial partnerships during clinical development to bring LIB-01 to commercialization on the world market.

Dicot Pharma is listed on Nasdaq First North and has approximately 16,750 shareholders. FNCA Sweden AB is appointed Certified Adviser. For more information, please visit www.dicotpharma.com.

This is a translation from the Swedish original. In case of differences between versions, the Swedish version prevails.